Finally, these studies identified ERK as a downstream target of miR-876 action in melanoma, suggesting miR-876 loss as an additional mechanism to activate the MAPK pathway in melanoma, as well as indicating the potential for combining miR-876 replacement therapy with existing selective BRAF inhibitors in melanoma. The gene discussed is BRAF; the disease is melanoma.